Moderna lifts veil on pipeline

At a presentation at the JPMorgan Healthcare Conference on Tuesday, mRNA vaccines and therapeutics company Moderna Therapeutics Inc. (Cambridge, Mass.) CEO Stephane Bancel outlined the company's pipeline as it prepares to start clinical studies of two more programs. Five of the 12 programs Moderna lists in its pipeline are already in the clinic.

Moderna has submitted INDs for mRNA-1388, which is a vaccine against Chikungunya; and mRNA-2416, which is an immunotherapy targeting OX40 ligand (OX40L; CD134L) to treat cancer. Moderna declined to say when it expects to begin trials of the candidates...